期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 20, 页码 13852-13865出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01081
关键词
-
资金
- AMED [JP20fk0108519, JP21ak0101121]
- Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) [JP22ama121031]
- JSPS KAKENHI [JP17H06349, 19H02854]
- Sumitomo Foundation
The study reports a new class of covalent inhibitors of 3CLpro with strong antiviral activity against SARS-CoV-2 replication, showing potential in terms of biochemical efficiency and pharmacokinetic properties.
The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3C-like protease (3CLpro) is a promising target for COVID-19 treatment. Here, we report a new class of covalent inhibitors of 3CLpro that possess chlorofluoroacetamide (CFA) as a cysteine-reactive warhead. Based on an aza-peptide scaffold, we synthesized a series of CFA derivatives in enantiopure form and evaluated their biochemical efficiency. The data revealed that 8a (YH-6) with the R configuration at the CFA unit strongly blocks SARS-CoV-2 replication in infected cells, and its potency is comparable to that of nirmatrelvir. X-ray structural analysis showed that YH-6 formed a covalent bond with Cys145 at the catalytic center of 3CLpro. The strong antiviral activity and favorable pharmacokinetic properties of YH-6 suggest its potential as a lead compound for the treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据